

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **C-LINK SQUARED LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1463)**

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that with effect from 7 June 2021, Dr. Zeng Jianhua has been appointed as an independent non-executive Director.

#### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of C-Link Squared Limited (the “**Company**”) is pleased to announce that Dr. Zeng Jianhua (“**Dr. Zeng**”) has been appointed as an independent non-executive Director (the “**INED**”), with effect from 7 June 2021.

Dr. Zeng Jianhua, aged 37, has over nine years of experience in the biomedical and health industry. In June 2011, Dr. Zeng founded Wuhan HuaTai Biotechnology Company Limited\* (武漢華肽生物科技有限公司) (“**Wuhan Biotechnology**”), a company primarily engaged in the development of anti-aging technologies and products and sale of cosmetics, and has been serving as the chairman of Wuhan Biotechnology since then. He took part in the invention of certain patents including methods of protein purification and hair care products for prevention of white hair. Dr. Zeng has also been the chairman of Jiaxing JiuTai Biotechnology Company Limited\* (嘉興玖肽生物技術有限公司), a company primarily engaged in the development of biomedical engineering technologies, since December 2018. Since May 2015, he has served as the executive chairman of Youth’s Innovation and Entrepreneurship Alliance of Communist Youth League in Hubei Province\* (湖北青年創新創業者聯盟), the People’s Republic of China (the “**PRC**”).

In June 2008, Dr. Zeng received a Bachelor's degree in biomedical engineering from Huazhong University of Science and Technology in the PRC. In June 2012, he received a Doctor of Medicine in pharmacology from the Huazhong University of Science and Technology in the PRC.

Dr. Zeng does not hold any other position within the Group and has not held any directorship in any other public listed company in the past three years. Dr. Zeng has entered into a letter of appointment with the Company for a fixed term of three years commencing on 7 June 2021 and is subject to retirement by rotation and re-election in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company. Dr. Zeng is presently entitled to receive a director's fee of HK\$200,000 per annum. His emolument has been reviewed by the remuneration committee of the Company and determined by the Board by reference to his responsibilities and duties within the Company and the prevailing market conditions.

As at the date of this announcement, Dr. Zeng does not have any interest in any shares or underlying shares or debentures of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company. Dr. Zeng has confirmed that he met the independence criteria as set out in Rule 3.13 of the Listing Rules. Save as disclosed above, there is no other information which is disclosable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there are no other matters relating to the appointment of Dr. Zeng that need to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Dr. Zeng to the Board.

*\* For identification purposes only*

By order of the Board  
**C-Link Squared Limited**  
**Ling Sheng Hwang**

*Chairman of the Board and executive Director*

Hong Kong, 7 June 2021

*As at the date of this announcement, the executive Directors are Mr. Ling Sheng Hwang and Mr. Ling Sheng Chung, the non-executive Director is Mr. Ling Sheng Shyan, and the independent non-executive Directors are Ms. Eugenia Yang, Mr. Lee Yan Kit, Mr. Wong Son Heng and Dr. Zeng Jianhua.*